baber/WOPTO huggingface dataset:
Patent NZ-589397-A (NZ)
Title: Fungicidal compositions comprising a dihalomethylidene-benzonorbornene derivative and chlorothalonil
Inventor: TOBLER HANS
IPC: A01N43/56
Filed: 2008-04-23
Abstract: Disclosed are compositions comprising chlorothalonil and a dihalomethylidene-benzonorbornene derivative represented by the general formula (I), wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo. Also disclosed is a method of controlling diseases on useful plants or on propagation material thereof caused by phytopathogens, comprising applying the said composition to the plants. (62) Divided Out of 580186
Patent NZ-597535-A (NZ)
Title: Chemically modified ligase cofactors, donors and acceptors
Inventor: ZON GERALD
IPC: C12N9/00
Filed: 2010-07-06
Abstract: Patent No. 597535 Disclosed is a method for a detecting a mutation in a target nucleic acid, said method comprising: incubating said target nucleic acid in a reaction mixture comprising a cofactor dependent nucleic acid ligase, a modified ATP ligase cofactor, an optionally modified donor polynucleotide and an optionally modified acceptor polynucleotide; and monitoring ligation of said donor and acceptor polynucleotides, wherein the amount of ligation is indicative of the presence or absence of said mutation and wherein the presence of said modified ATP ligase cofactor, said optionally modified donor polynucleotide and said optionally modified acceptor polynucleotide, decreases or inhibits ligation of non-complementary nucleic acid relative to ligation efficiency of the corresponding reaction wherein said ATP ligase cofactor, donor polynucleotide and acceptor polynucleotide are unmodified.
Patent NZ-600470-A (NZ)
Title: Anti-c4.4a antibodies and uses thereof
Inventor: MAYER-BARTSCHMID ANKE
IPC: G01N33/53
Filed: 2010-12-08
Abstract: Disclosed is an antibody which binds to C4.4a comprising CDR sequences of FSNAWMSWV, VSYISSSGSTIYYADSVKGR, AREGLWAFDY, TGSSSNIGAGYVVH, DNNKRPS and CAAWDDRLNGPV.
Patent NZ-603327-A (NZ)
Title: Riser components and methods for making the same
Inventor: MCTERNAN KEITH RICHARD
IPC: B23P11/00
Filed: 2011-04-05
Abstract: A method for making a riser component. A coupler (44) is positioned adjacent an end of a tube (42) such that a region (52) of the coupler forms an interface with the tube’s end (50). The region includes a material (in some embodiments an aluminum alloy), and the tube’s end includes a groove (54) and another material (in some embodiments a steel alloy) that is different than the region’s material. The coupler is positioned adjacent the tube’s end, the material of the coupler’s region that forms the interface with the tube’s end is not disposed in the groove of the tube’s end. A region of the coupler is heated to increase the region’s malleability. Pressure is exerted on the region of the coupler to plastically deform the region to insert some of the region’s material into the groove in the tube’s end. By fixing the coupler to the tube in this manner, the coupler may be strongly secured to the tube, and thus able to withstand high, dynamic loads frequently experienced in service. Also, the material of the coupler may be different than the material of the tube, and thus the material of the coupler may be lighter than the material of the tube. This allows one to design a riser component that is lighter than a conventional steel riser component having a steel tube and steel flanges, but that can withstand the high, dynamic loads frequently experienced in service.
Patent NZ-603829-A (NZ)
Title: Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
Inventor: HARTLEPP FELIX
IPC: C07K16/46
Filed: 2011-05-05
Abstract: Discloses isolated bivalent antibodies or a bivalent fragment thereof to a low density lipoprotein-related protein 6 (LRP6) that potentiates a Wnt signal by clustering one or more LRP6 receptors in the presence of an unblocked LRP6 binding protein, and an isolated monovalent antibody or monovalent binding fragment thereof to a LRP6 that avoids potentiating a Wnt signal by clustering one or more LRP6 receptors in the presence of an unblocked LRP6 binding protein. Further discloses specific sequence structures of such antibodies and use in the treatment of cancer.
Patent NZ-604002-A (NZ)
Title: Method and system for pulp processing using cold caustic extraction with alkaline filtrate reuse
Inventor: LEITE MARCELO MOREIRA
IPC: D21C3/02
Filed: 2010-08-18
Abstract: 604002 Disclosed herein is a method for pulp manufacturing using cold caustic extraction for production of dissolving pulp and the use of the method in a kraft process, comprising: - delignifying organic materials in one or more digesters and treating a resulting brown stock to yield semi-purified pulp for use In the production of dissolving pulp; - extracting the semi-purified pulp with a caustic solution during a cold caustic extraction process to yield a purified pulp and a solution containing hemicellulose; - washing the purified pulp and collecting a spent washing liquid therefrom while separating the hemicellulose-containing solution from the purified pulp; - combining the spent washing liquid and the hemicellulose-containing solution to form an alkaline filtrate; - concentrating the alkaline filtrate to form a concentrated alkaline filtrate without purifying the hemicellulose-containing solution or alkaline filtrate to substantially remove the hemicellulose therein; and - utilizing at least a portion of the concentrated alkaline filtrate in said digester in connection with production of dissolving pulp.
Patent NZ-604649-A (NZ)
Title: Crystalline forms of kinase inhibitors
Inventor: HOFFMAN DOUG H
IPC: C07D495/04
Filed: 2011-06-08
Abstract: Disclosed herein are citrate salts of N-(4-{ 4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl} phenyl)-N’-(3-fluorophenyl)urea and crystalline forms thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.
Patent NZ-611062-A (NZ)
Title: Watertight flashlight
Inventor: KHOURY EDWARD JOSEPH
IPC: A47F7/10
Filed: 2011-06-20
Abstract: 605854 The disclosure relates to a torch comprising a housing (2), a battery housing (4) which is mounted therein and which has a pressure switch (5) on one end, and an end cap (6) with a push button (7) which is actively connected to the pressure switch. According to the disclosure, in order to provide a waterproof and at the same time robust torch, a sealing element (13) is arranged between the push button and the pressure switch.
Patent NZ-611614-A (NZ)
Title: Compositions and methods for treating amyloid plaque associated symptoms
Inventor: HOLTZMAN DAVID
IPC: C12P21/08
Filed: 2011-12-02
Abstract: Disclosed is the use of at least one anti-ApoE antibody in the manufacture of a medicament for reversing at least one symptom or sign of amyloid-beta plaque associated symptoms in a subject, wherein the anti-ApoE antibody does not affect plasma cholesterol level. Also disclosed is the use of at least one anti-ApoE antibody in the manufacture of a medicament for decreasing the amyloid plaque load in the brain of a subject.
Patent NZ-619458-A (NZ)
Title: Mtor kinase inhibitors for oncology indications and diseases associated with the mtor/pi3k/akt pathway
Inventor: ELSNER JAN
IPC: C07D487/04
Filed: 2009-10-27
Abstract: The disclosure relates to dihydropyrazino[2,3-h]pyrazin-2(1H)-one derivative compounds of structural formula shown herein or a salt, tautomer or stereoisomer thereof, wherein: X is halogen, B(OR+)2 or Sn(R++)3; R2 is H, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aralkyl, or substituted or unsubstituted cycloalkylalkyl; R3 is H, or a substituted or unsubstituted C1-8 alkyl; each R+ is independently hydrogen or substituted or unsubstituted C1-3 alkyl, or each R+, together with the boron atom and the atoms to which they are attached, form a cyclic boronate; and R++ is a C1-4 alkyl. These compounds are suitable for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions.
Patent NZ-629649-A (NZ)
Title: Toxic peptide production, peptide expression in plants and combinations of cysteine rich peptides
Inventor: KENNEDY ROBERT M
IPC: C12N15/82
Filed: 2013-03-08
Abstract: Disclosed is a protein comprised of an Endoplasmic Reticulum Signal Peptide (ERSP) operably linked to a Cysteine Rich Insecticidal Protein (CRIP) such as an Inhibitor Cysteine Knot (ICK) motif protein wherein said ERSP is the N-terminal of said protein (ERSP-ICK).
Patent NZ-702876-A (NZ)
Title: Method of reducing sag of a ceiling tile and ceiling tile
Inventor: YEUNG LEE K
IPC: E04C2/288
Filed: 2013-05-23
Abstract: Sag in ceiling tiles is reduced by the present coated ceiling tile and method which decreases sag in the coated ceiling tiles. Calcined gypsum and water are combined to form a coating which is applied to the back side of a base ceiling tile in a thin layer of about 100 micrometer to about 1000 micrometers. The coating optionally includes a set time modifier. This method makes a coated ceiling tile from a base ceiling tile having a front side and a back side opposing the front side. The coating is applied to the back side of the base ceiling tile, the coating comprising an interlocking matrix of calcium sulfate dihydrate. Optionally, remnants of the set time modifier are present within interstices in the gypsum matrix. The remnants of the set time molecule include ions, molecules, particles or combinations thereof.
Patent NZ-703573-A (NZ)
Title: Feijoa fruit extract
Inventor: FOO LAI YEAP
IPC: A61P37/02
Filed: 2013-06-10
Abstract: The invention relates to a feijoa fruit extract. In particular the invention relates to therapeutic uses of a feijoa fruit extract, processes for preparing the extract, and compositions comprising the extract. The feijoa fruit extract of the invention can be used in the treatment and prevention of rheumatoid arthritis and Type-2 diabetes.
Patent NZ-704748-A (NZ)
Title: Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
Inventor: RABOISSON PIERRE JEAN-MARIE BERNARD
IPC: C07D333/46
Filed: 2013-08-28
Abstract: Inhibitors of HBV replication of Formula (Ia) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R1, R2 and R4 have the meaning as defined herein. The present invention also relates to pharmaceutical compositions containing these inhibitors and to their use, alone or in combination with other HBV inhibitors, in HBV therapy.
Patent NZ-712079-A (NZ)
Title: Purine derivatives as cb2 receptor agonists
Inventor: ROGERS-EVANS MARK
IPC: A61P3/00
Filed: 2014-04-28
Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R4 are defined as in the description and in the claims. The compound of formula (I) is a CB2 receptor agonist and can be used as a medicament.
Patent NZ-720626-A (NZ)
Title: Triaging of patients having asymptomatic hematuria using genotypic and phenotypic biomarkers
Inventor: DALPHIN MARK
IPC: G01N33/574
Filed: 2014-11-20
Abstract: New methods for identifying patents with hematuria who are at low risk of having urothelial cancer (UC) include combining selected phenotypic variables with levels of genotypic expression into a new metric, the “G+P INDEX.” The G+P INDEX combines age, sex, smoking history, presence of hematuria, and frequency of hematuria with genotypic expression of the genetic markers, MDK, CDC2, HOXA13, IGFBP5, and optionally IL8Rb, then determining of the G+P INDEX value obtained for a patient is within one of three groups, either: (1) at High Risk of UC, (2) at Risk of UC, or (3) at Low Risk of UC.
Patent NZ-731708-A (NZ)
Title: A seat cushion
Inventor: DOWNES SCOTT
IPC: A47C7/20
Filed: 2015-07-31
Abstract: There is disclosed a seat cushion (10), including a forward portion (22) for supporting the upper thighs of a sitter. The forward portion (22) is formed from at least a first resilient material. The seat cushion (10) further includes a rearward portion (24) for supporting the buttocks of the sitter. The rearward portion (24) is formed from a second resilient material, which is relatively softer than the first resilient material. The seat cushion (10) further includes an upwardly open transverse crevice (30) defined between the forward portion (22) and the rearward portion (24). The seat cushion (10) further includes a pair of intermediate portions (38, 40) for supporting the ischial tuberosities of the sitter. The intermediate portions (38, 40) are formed from a third resilient material, which is relatively firmer than the second resilient material. Each intermediate portion (38, 40) is embedded within the forward and rearward portions (22, 24) and extending across the transverse crevice (30). The intermediate portions (38, 40) are laterally spaced apart such that, in use, each intermediate portion (38, 40) is locatable below a respective ischial tuberosity of the sitter. This configuration allows the ischial tuberosities of a sitter of varying body size and shape to be firmly supported compared to other parts of the buttocks through the intermediate portions of the cushion while also resisting forward movement of the ischial tuberosities thereby promoting correct posture. Due to the shape of the intermediate portions, gradual decrease in firmness in the forward direction is experienced by a respective upper thigh of a sitter to allow a decrease in pressure to that area to provide enhanced comfort and to help promote blood circulation.
Patent NZ-733104-A (NZ)
Title: Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
Inventor: RODGERS JAMES D
IPC: A61P35/00
Filed: 2006-12-12
Abstract: Disclosed are pyrrolo[2,3-b]pyridine and pyrrolo[2,3-b]pyrimidine compounds of Formula I, salts thereof and methods for their preparation. An example of the compound is 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1- yl]propanenitrile. Compounds of Formula I modulate the activity of Janus kinases and are useful in the treatment of diseases such as immune-related diseases, skin disorders, myeloid proliferative disorders, cancer and other diseases.
Patent NZ-736642-A (NZ)
Title: Short synthetic peptide for treatment and/or prophylaxis of autoimmune and inflammatory disorders
Inventor: TSAO YEOU-PING
IPC: C07K4/12
Filed: 2016-04-14
Abstract: Disclosed herein are use of a synthetic peptide for the manufacture of a medicament for the treatment and/or prophylaxis of a disease, disorder and/or a condition related to inflammation. The synthetic peptide is consisting of 7 consecutive amino acid residues set forth as X1X2X3X4X5X6 X7 (SEQ ID NO: 1), wherein, X1 is alanine (A), aspartic acid (D), asparagine (N), leucine (L), phenylalanine (F), or valine (V); X2 is alanine (A), isoleucine (I), leucine (L), or valine (V); X3 is phenylalanine (F), tyrosine (Y) or tryptophan (W); X4 is arginine (R) or lysine (K); X5 is valine (V), methionine (M), isoleucine (I), leucine (L), or glutamine (Q); X6 is arginine (R), glutamine (Q), lysine (K) or proline (P); X7 is serine (S) or threonine (T); and each X2, X3, X4, X6 and X7 are independently L-form amino acid residues.
Patent NZ-749249-A (NZ)
Title: Pre-cast concrete formwork, wall system and method of construction
Inventor: DARESTANI ARIO YOUSEFI
IPC: E04G11/06
Filed: 2017-07-26
Abstract: There is a need for providing improved formwork and a wall system that reduces the overall time required for construction and also provide a higher quality finish. There is also a need to provide modular formwork which can be configured into one of many possible configurations to allow building of varying dimensions to be built more easily. The present invention relates to the field of construction and more specifically relates to pre-cast concrete formwork, a wall system and an associated method of forming a wall system in a structure. The formwork comprising: a first pre-cast concrete wall panel and a second pre-cast concrete wall panel, the first wall panel being adapted for being positioned in a spaced relationship with the second wall panel; a hollow core defined by oppositely arranged surfaces of the first and second wall panels, the core being adapted for receiving wet concrete; and a connecting arrangement for inter-connecting the first wall panel with the second wall panel in the spaced relationship, the connecting arrangement extending generally in an outwardly direction relative to said oppositely arranged surfaces of the first and second wall panels. The formwork also includes the joiner members to connect wall panels together and also includes all reinforcing bars that may be required at operational phase.
Patent NZ-751237-A (NZ)
Title: Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
Inventor: DONELLO JOHN E
IPC: A61K31/662
Filed: 2014-03-04
Abstract: The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 such as compounds of Formula III and related structures.
Patent NZ-759551-A (NZ)
Title: Two-filter light detection devices and methods related to same
Inventor: CAI XIUYU
IPC: G01N21/64
Filed: 2018-11-20
Abstract: Light detection devices and corresponding methods are provided. The devices include a reaction structure to contain a reaction solution and at least one reaction site that generates light emissions in response to incident excitation light after treatment with the reaction solution. The devices also include a plurality of light sensors and device circuitry. The devices further include a plurality of light guides extending toward at least one corresponding light sensor from input regions that receive the excitation light and the light emissions from at least one corresponding reaction recess. The light guides comprise a first filter region that filters the excitation light and permits the light emissions of a first wavelength to pass to the at least one corresponding light sensor, and a second filter region that filters the excitation light and the permits light emissions of a second wavelength to pass to the at least one corresponding light sensor.
Patent NZ-766175-A (NZ)
Title: Insulating glazing and method for producing same
Inventor: SCHREIBER WALTER
IPC: E06B3/663
Filed: 2018-12-20
Abstract: Insulating glazings are mass-produced in a few large factories of the individual manufacturers, and the finished insulating glazings are then delivered to many locations for further processing into components (windows, doors, etc.) or for direct construction-site use (for instance, for façade glazings or roof glazings). These can be at altitudes significantly different from the manufacturing site such that in the case of a hermetically sealed insulating glazing, as a result of the changed pressure at the site of further processing or use, bending of the panes can occur and can have a noticeable adverse effect on the optical quality of the insulating glazing. Provided is an insulating glazing which comprises a first pane and a second pane; a peripheral spacer between the first pane and the second pane which is fixedly connected to the first and second pane, in each case in a water vapour-tight manner, and which has at least two pane contact walls extending in parallel, an outer wall and a glazing interior wall and also an interior; and a water-tight sealant strip running around the outer wall of the spacer between the first and second pane, wherein at least one pressure-equalizing element is inserted into the sealant strip and the spacer, which pressure-equalizing element is open, on the one hand, to the surrounding atmosphere and, on the other hand, to the interior of the spacer or to the glazing interior between the first and the second pane and is designed in such a way that it provides a gas connection, which is time-limited on account of ageing and/or atmospheric influences, with pressure-equalizing function between the atmosphere and the interior of the spacer or the glazing interior.
Patent PT-103575-A (PT)
Title: Dispositivo para protecção de motociclistas
Inventor: ALMEIDA CARLOS JORGE LAGE DE
IPC: E01F15/04
Filed: 2006-10-02
Abstract: A PRESENTE PATENTE REFERE-SE A UM DISPOSITIVO DE PROTECÇÃO CONTÍNUO, DESTINADO À SALVAGUARDA DOS MOTOCICLISTAS, EM CASO DE ACIDENTE, PRODUZINDO O SEU EFEITO PRÁTICO AO SER COLOCADO NA PARTE INFERIOR DAS BARREIRAS DE RETENÇÃO, ENTRE O PERFIL EM W E O SOLO. O DISPOSITIVO, REPRESENTADO NA FIGURA 1, É CONSTITUÍDO POR DOIS MATERIAIS DISTINTOS, O PRIMEIRO, COM VOCAÇÃO ESTRUTURAL (4) E O SEGUNDO, RUGOSO E FLEXÍVEL (1) E QUE SERVE PARA EVITAR DESACELERAÇÕES BRUSCAS, E EM SIMULTÂNEO, O ESCORREGAMENTO AO LONGO DA PROTECÇÃO. A MONTAGEM DESTE SISTEMA É FÁCIL E RÁPIDA, DEVIDO À UTILIZAÇÃO DE UMA PLACA METÁLICA DE LIGAÇÃO (3) QUE UNE OS ELEMENTOS ESTRUTURAIS DO DISPOSITIVO ENTRE SI E ENTRE AQUELE E A BARREIRA (2) AJUDANDO A DISSIPAR A ENERGIA DO IMPACTO. EXISTE A POSSIBILIDADE DE INCLUIR NO DISPOSITIVO, BANDAS REFLECTORAS DESTINADAS A ALERTAR OS CONDUTORES PARA POSSÍVEIS PERIGOS.
Patent PT-103844-A (PT)
Title: Método de isolamento de células precursoras a partir do cordão umbilical humano utilizando enzimas de origem vegetal
Inventor: SOARES RITA ISABEL GANCHAS
IPC: C12N5/22
Filed: 2007-10-04
Abstract: A PRESENTE INVENÇÃO REFERE-SE À UTILIZAÇÃO DE ENZIMAS OU COMPLEXOS ENZIMÁTICOS DE ORIGEM ESTRITAMENTE VEGETAL, NOMEADAMENTE ENZIMAS COM ACTIVIDADE PEPTIDICA, MAIS ESPECIFICAMENTE A PAPAINA, PARA A DIGESTÃO DO CORDÃO UMBILICAL HUMANO COM O FIM DE ISOLAR CÉLULAS ÍNTEGRAS, VIÁVEIS, COM CAPACIDADE DE ADESÃO E EXPANSÃO/MULTIPLICAÇÃO EM CULTURA. A PRESENTE INVENÇÃO CONSTITUI A BASE PARA DUM MÉTODO DE ISOLAMENTO DE CÉLULAS PRECURSORAS HUMANAS, CUJO PASSO DE DISSOCIAÇÃO DAS CÉLULAS DO TECIDO É LIVRE DA UTILIZAÇÃO DE COMPOSTOS DE ORIGEM ANIMAL, COM VISTA À CRIAÇÃO DE UM PROTOCOLO DE ISOLAMENTO QUE ORIGINE CÉLULAS MAIS SEGURAS PARA FUTURAS APLICAÇÕES DE TERAPIA CELULAR.
Patent PT-104888-A (PT)
Title: Biopolímero bacteriano contendo fucose
Inventor: OLIVEIRA RUI MANUEL FREITAS
IPC: C08B37/00
Filed: 2009-12-15
Abstract: A PRESENTE INVENÇÃO DIZ RESPEITO A UM BIOPOLÍMERO PRODUZIDO POR VIA MICROBIANA E QUE CONTÉM FUCOSE NA SUA COMPOSIÇÃO. ESTE BIOPOLÍMERO CONSISTE NUM POLISSACÁRIDO NO QUAL A FUCOSE REPRESENTA PELO MENOS 10% DA SUA COMPOSIÇÃO, POSSUINDO COMO COMPONENTES NÃO SACARÍDEOS GRUPOS ACILO, NOMEADAMENTE, ACETATO, PIRUVATO E SUCCINATO. OUTRO DOS ASPECTOS DA PRESENTE INVENÇÃO DIZ RESPEITO AO PROCESSO DE OBTENÇÃO DO BIOPOLÍMERO, SENDO ESTE OBTIDO POR CULTIVO DE MICRORGANISMOS, EM PARTICULAR A PARTIR DE CULTURAS DE ENTEROBACTER A47 (DSM 23139), UTILIZANDO COMO FONTE DE CARBONO PREFERENCIAL O GLICEROL E/OU MISTURAS CONTENDO GLICEROL. O POLÍMERO DA PRESENTE INVENÇÃO PODE SER UTILIZADO, EM VÁRIOS TIPOS DE APLICAÇÕES INDUSTRIAIS, COMO POR EX. NAS INDÚSTRIAS FARMACÊUTICA, COSMÉTICA E AGRO-ALIMENTAR, E NO TRATAMENTO DE RESÍDUOS INDUSTRIAIS, COMO POR EX. NA RECUPERAÇÃO DE ÓLEOS E METAIS.